BSX FY 2025 Earnings Report — Boston Scientific Corporation Revenue & Financial Results | Market Cap Arena

Boston Scientific CorporationBSX

FY 2025 Earnings

Reported February 17, 2026

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2025	Prior Q	FY 2024	QoQ Change	YoY Change
Revenue	$20.1B	—	$16.7B	—	19.9%
Op. Income	$4.0B	—	$2.6B	—	50.7%
Gross Margin	69.0%	—	61.3%	—	7.7pp
Net Margin	14.4%	—	11.1%	—	3.3pp
EPS (Diluted)	$1.94	—	$1.25	—	55.2%
Free Cash Flow	$3.7B	—	$2.6B	—	38.3%

Revenue Flow

Item	Amount
REVENUE	$20.1B
Cost of Revenue	$6.2B
GROSS PROFIT	$13.9B
R&D Expenses	$2.1B
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$6.9B
Other Expenses	$943M
Operating Expenses	$9.9B
Cost & Expenses	$16.1B
OPERATING INCOME	$4.0B
Interest Income	$0
Interest Expense	$349M
Other Income/Expenses	-$586M
INCOME BEFORE TAX	$3.4B
Income Tax Expense	$493M
Net Income from Continuing Ops	$2.9B
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$2.9B
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$2.9B
D&A	$0
EBIT	$3.7B
EBITDA	$3.7B
EPS	$2
EPS Diluted	$2

Income Statement

Item	Amount
REVENUE	$20.1B
Cost of Revenue	$6.2B
GROSS PROFIT	$13.9B
R&D Expenses	$2.1B
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$6.9B
Other Expenses	$943M
Operating Expenses	$9.9B
Cost & Expenses	$16.1B
OPERATING INCOME	$4.0B
Interest Income	$0
Interest Expense	$349M
Other Income/Expenses	-$586M
INCOME BEFORE TAX	$3.4B
Income Tax Expense	$493M
Net Income from Continuing Ops	$2.9B
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$2.9B
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$2.9B
D&A	$0
EBIT	$3.7B
EBITDA	$3.7B
EPS	$2
EPS Diluted	$2

Cash Flow Statement

Item	Amount
Net Income	$2.9B
Depreciation & Amortization	$1.4B
Stock-Based Compensation	$299M
Deferred Income Tax	$0
Other Non-Cash Items	$221M
Change in Working Capital	-$246M
OPERATING CASH FLOW	$4.5B
Capital Expenditure	-$876M
Acquisitions (Net)	-$1.6B
Purchases of Investments	$0
Sales/Maturities of Investments	$0
Other Investing Activities	-$171M
NET CASH FROM INVESTING	-$2.6B
Net Debt Issuance	-$491M
Common Stock Repurchased	$0
Common Dividends Paid	$0
Other Financing Activities	-$186M
NET CASH FROM FINANCING	-$395M
FREE CASH FLOW	$3.7B
Net Change in Cash	$1.5B

Balance Sheet

Item	Amount
Cash & Equivalents	$2.0B
Short-Term Investments	$0
Net Receivables	$2.9B
Inventory	$2.9B
Other Current Assets	$580M
TOTAL CURRENT ASSETS	$8.8B
PP&E (Net)	$4.5B
Goodwill	$18.3B
Intangible Assets	$7.0B
Long-Term Investments	$842M
Tax Assets	$3.7B
Other Non-Current Assets	$559M
TOTAL NON-CURRENT ASSETS	$34.9B
TOTAL ASSETS	$43.7B
Account Payables	$1.1B
Short-Term Debt	$389M
Deferred Revenue	$313M
Other Current Liabilities	$2.2B
TOTAL CURRENT LIABILITIES	$5.4B
Long-Term Debt	$11.5B
Deferred Revenue NC	$369M
Deferred Tax Liabilities	$220M
Other Non-Current Liabilities	$1.1B
TOTAL NON-CURRENT LIABILITIES	$13.8B
TOTAL LIABILITIES	$19.2B
Common Stock	$17M
Additional Paid-In Capital	$21.5B
Retained Earnings	$5.6B
Treasury Stock	-$2.3B
Accum. Other Comp. Income	-$610M
Other Equity	$1M
TOTAL STOCKHOLDERS' EQUITY	$24.2B
Minority Interest	$239M
TOTAL EQUITY	$24.5B
TOTAL LIABILITIES & EQUITY	$43.7B
Total Debt	$12.4B
Net Debt	$10.4B